Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Secondary Adrenal Insufficiency Associated with Megestrol Acetate in a Patient with Lung Cancer

Megestrol Acetate와 관련된 이차성 부신기능저하증의 폐암 1예

  • Park, Ji Chan (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Park, Suk Young (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 박지찬 (가톨릭대학교 의과대학 내과학교실) ;
  • 박석영 (가톨릭대학교 의과대학 내과학교실)
  • Received : 2009.06.14
  • Accepted : 2009.07.07
  • Published : 2009.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Loss of appetite is an important factor in the quality of life for advanced cancer patients. Megestrol acetate is used to stimulate appetite, but it can cause suppression of the pituitary adrenal axis due to the affinity of the glucocorticoid receptor. Adrenal insufficiency is a life threatening disorder if left, untreated, but the initial clinical symptoms of the patients are vague. Awareness of the glucocorticoid-like activity of megestrol acetate and its side effects are important for the diagnosis of adrenal insufficiency. We present a case of secondary adrenal insufficiency associated with megestrol acetate in a patient with lung cancer.

식욕 저하는 진행성 암환자에게 삶의 질을 저하시키는 중요한 요인으로서 이에 대한 보조 치료제로 megestrol acetate는 임상적인 호전을 유도할 수 있다. 이 약제는 부신기능저하의 부작용이 발생할 수 있으며, 암환자에게서의 부신기능저하와 관련된 증상은 기저 질환과 암 치료로 인한 부작용 등으로 간과될 수 있다. Megestrol acetate를 복용하거나 중단한 환자에서 부신기능저하와 관련된 증상과 검사소견이 있을 때 부신기능저하는 생명에 위협을 줄 수 있기 때문에 이에 대하여 항상 인지를 하고 적절한 검사와 치료가 필요함을 염두에 둬야 한다. 저자들은 폐암 환자에서 megestrol acetate 복용 후 발생한 이차성 부신기능저하증 1예를 경험하여 문헌 고찰과 함께 보고하는 바이다.

Keywords

References

  1. Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr 2006;25:711-5 https://doi.org/10.1016/j.clnu.2006.05.009
  2. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol: a summary of food and drug administration experience and a review of the literature. Arch Intern Med 1997; 157:1651-6 https://doi.org/10.1001/archinte.157.15.1651
  3. Kontula K, Paavonen T, Luukkainen T, Andersson LC. Binding of progestins to the glucocorticoid receptor: correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochem Pharmacol 1983;32:1511-8 https://doi.org/10.1016/0006-2952(83)90474-4
  4. Pascual Lopez A, Roqué i Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004;27:360-9 https://doi.org/10.1016/j.jpainsymman.2003.09.007
  5. Loprinzi CL, Fonseca R, Jensen MD. Megestrol acetateinduced adrenal suppression. J Clin Oncol 1996;14:689 https://doi.org/10.1200/JCO.1996.14.2.689
  6. Ron IG, Soyfer V, Goldray D, Inbar MJ, Weisman Y. A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy. Eur J Cancer 2002;38:1490-4 https://doi.org/10.1016/S0959-8049(02)00077-1
  7. Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer 1999;86:1044-9 https://doi.org/10.1002/(SICI)1097-0142(19990915)86:6<1044::AID-CNCR21>3.0.CO;2-C
  8. Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM. High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate. J Endocrinol Invest 2006; 29:136-40 https://doi.org/10.1007/BF03344086
  9. Raedler TJ, Jahn H, Goedeken B, Gescher DM, Kellner M, Wiedemann K. Acute effects of megestrol on the hypothalamic-pituitary-adrenal axis. Cancer Chemother Pharmacol 2003;52:482-6 https://doi.org/10.1007/s00280-003-0697-6
  10. Salvatori R. Adrenal insufficiency. JAMA 2005;294:2481-8 https://doi.org/10.1001/jama.294.19.2481